Research and Markets: Global Acute Myeloid Leukemia Epidemiology and Patient Flow Analysis 2015

<0> Research and Markets: Global Acute Myeloid Leukemia Epidemiology and Patient Flow Analysis 2015 </0>

<0> Research and MarketsLaura Wood, Senior ManagerFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: </0>

() has announced the addition of the report to their offering.

The report provides insights into Acute Myeloid Leukemia epidemiology, Acute Myeloid Leukemia diagnosed patients, and Acute Myeloid Leukemia treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Acute Myeloid Leukemia derived from epidemiological analysis, percentage of patients diagnosed with Acute Myeloid Leukemia, and percentage of patients treated with Acute Myeloid Leukemia therapy.

The study helps executives estimate Acute Myeloid Leukemia market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.

The report provides estimates and forecasts of Acute Myeloid Leukemia prevalence, Acute Myeloid Leukemia diagnosis rate, and Acute Myeloid Leukemia treatment rate for the period 2014 - 2020. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan.

1. Acute Myeloid Leukemia: Disease Definition

2. Global Acute Myeloid Leukemia Patient Flow

3. Acute Myeloid Leukemia Patient Flow in the US

4. Acute Myeloid Leukemia Patient Flow in Europe

5. Acute Myeloid Leukemia Patient Flow in Germany

6. Acute Myeloid Leukemia Patient Flow in France

7. Acute Myeloid Leukemia Patient Flow in Spain

8. Acute Myeloid Leukemia Patient Flow in Italy

9. Acute Myeloid Leukemia Patient Flow in UK

10. Acute Myeloid Leukemia Patient Flow in Japan

11. Appendix

For more information visit

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.